Rafael Amado - Articles and news items

GlaxoSmithKline logo

Trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination demonstrated overall survival benefit compared to vemurafenib

Industry news / 18 July 2014 / GlaxoSmithKline

…phase III BRAF V600-mutant metastatic melanoma study stopped early.

GlaxoSmithKline logo

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes

Industry news / 26 June 2014 / GlaxoSmithKline

GlaxoSmithKline plc announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™)…

GlaxoSmithKline logo

GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting

Industry news / 2 June 2014 / GlaxoSmithKline

GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival…

GlaxoSmithKline logo

GSK launches global consortium with six renowned cancer research centres

Industry news / 5 December 2013 / GlaxoSmithKline

GlaxoSmithKline plc announced the formation of the Oncology Clinical and Translational Consortium…

GlaxoSmithKline logo

GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer

Industry news, News / 6 August 2013 / GlaxoSmithKline

“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline…”

GlaxoSmithKline logo

GSK receives positive CHMP opinion for REVOLADETM in thrombocytopenia associated with chronic hepatitis C infection

Industry news, News / 26 July 2013 / GlaxoSmithKline

“A sustained virologic response is the goal for treatment of hepatitis C infection…”

GlaxoSmithKline logo

GSK receives positive CHMP opinions for Tafinlar® (dabrafenib) and Tyverb® (lapatinib)

Industry news, News / 28 June 2013 / GlaxoSmithKline

The EMA’s CHMP is recommending marketing authorisation for two cancer drugs…

GlaxoSmithKline logo
GlaxoSmithKline logo

European submission for MEK monotherapy and BRAF/MEK combination therapy in metastatic melanoma

Industry news, News / 7 February 2013 / GlaxoSmithKline

GSK announced submission of a Marketing Authorisation Application…

GlaxoSmithKline logo
GlaxoSmithKline logo

Regulatory Update – GSK announces submissions in the EU and US for dabrafenib and trametinib

Industry news, News / 3 August 2012 / GlaxoSmithKline

GlaxoSmithKline announced regulatory submissions in the European Union and US…

GlaxoSmithKline logo

US Regulatory Update – Tykerb® (lapatinib)

Industry news, News / 12 July 2012 / GlaxoSmithKline

GlaxoSmithKline has withdrawn a supplemental New Drug Application to the US FDA for Tykerb…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...